18F-FDG PET/CT in Erdheim-Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker
Conclusion: 18F-FDG PET/CT results may act as a biomarker for the presence of a BRAF mutation, aid in establishing a diagnosis, guide biopsies, and gauge the treatment response in ECD patients. Axial and pelvic skeletal involvement is greater than previously reported.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Young, J. R., Johnson, G. B., Murphy, R. C., Go, R. S., Broski, S. M. Tags: Clinical Source Type: research